Crystalline and amorphous forms of...

Details Crystalline and amorphous forms of... Crystalline and amorphous forms of...

2008-01-29

2008-01-29

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S043000, C514S046000, C514S047000, C536S027800

Reexamination Certificate

active

07323451

ABSTRACT:
Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.

REFERENCES:
patent: 4916122 (1990-04-01), Chu
patent: 4957924 (1990-09-01), Beauchamp
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5190926 (1993-03-01), Chu
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5220003 (1993-06-01), Jung et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5539116 (1996-07-01), Liotta
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5559101 (1996-09-01), Weis et al.
patent: 5565438 (1996-10-01), Chu
patent: 5567688 (1996-10-01), Chu
patent: 5587362 (1996-12-01), Chu
patent: 5939402 (1999-08-01), Weis et al.
patent: 5990093 (1999-11-01), Schinazi et al.
patent: 6025335 (2000-02-01), Weis et al.
patent: 6194391 (2001-02-01), Schinazi et al.
patent: 6245749 (2001-06-01), Schinazi et al.
patent: 6297222 (2001-10-01), von Borstel et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6462174 (2002-10-01), Roberts
patent: 6566344 (2003-05-01), Gosselin et al.
patent: 6569837 (2003-05-01), Gosselin et al.
patent: 6723728 (2004-04-01), Hu et al.
patent: 2 206 878 (1997-03-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 355 131 (1996-09-01), None
patent: 875 971 (1961-08-01), None
patent: 6-293645 (1994-10-01), None
patent: WO89/02733 (1989-04-01), None
patent: WO89/03838 (1989-05-01), None
patent: WO90/00555 (1990-01-01), None
patent: WO91/16920 (1991-11-01), None
patent: WO91/18914 (1991-12-01), None
patent: WO91/19721 (1991-12-01), None
patent: WO92/08727 (1992-05-01), None
patent: WO92/15308 (1992-09-01), None
patent: WO92/18517 (1992-10-01), None
patent: WO93/00910 (1993-01-01), None
patent: WO 94/01138 (1994-01-01), None
patent: WO94/20523 (1994-09-01), None
patent: WO94/26273 (1994-11-01), None
patent: WO95/07086 (1995-03-01), None
patent: WO96/11204 (1996-04-01), None
patent: WO96/13512 (1996-05-01), None
patent: WO96/15132 (1996-05-01), None
patent: WO96/40164 (1996-12-01), None
patent: WO 99/45935 (1999-09-01), None
patent: WO 00/09531 (2000-02-01), None
Legeay et al. Eur. Polym. J. (1998), vol. 34, No. 10, pp. 1457-1465.
Arner, E.S.J., et al., “Mammalian Deoxyribonicleoside Kinases,”Pharm. Ther., 67(2), 155-186 (1995).
Berk, A.J., et al., “A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria,”J Biol Chem, 248(8):2722-2729 (1973).
Bestwick, R.K., et al., “Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells,”J. Biol. Chem., 257(16):9300-9304 (1982).
Bloch, A., et al. “The Role Of The 5′-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase,”J. Med. Chem., 10(5):908-12 (Sep. 1967).
Bridges, E.G., et al., “Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria,”J. Biol. Chem., 274(8):4620-4625 (Feb. 19, 1999).
Bridges, E.G., et al., “Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs,”Proc. Am. Assoc. Cancer Res., 38:414 (Mar. 1997).
Bridges, E.G., et al., “Inhibition of Mammalian DNA Polymerase-Associated 3′ to 5′ Exonuclease Activity by 5′-Monophosphates of 3′-Azido-3′-Deoxythymine and 3′-Amino-3′-Deoxythymidine,”Biochemical Pharmacology, 45(8):1571-1576 (1993).
Bryant, M.L., et al., “Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection,”Antimicrobial Agents and Chemotherapy, 45(1):229-235 (Jan. 2001).
Chang, C.N., et al., “Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (−)-2′,3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication,”Journal of Biological Chemistry, 267(20):13938-13942 (Jul. 15, 1992).
Chang, C.-N., et al., “Biochemical Pharmacology of (+)- and (−)-2′,3′-Dideoxy-3′-thiacytidine as Anti-hepatitis B Virus Agents,”J Biol Chem, 267(31), 22414-22420 (Nov. 5, 1992).
Chariot, P., et al., “Zidovudine-induced mitochondrial disorder with massive liver steatosis myopathy, lactic acidosis, and mitochondrial DNA depletion,”J. Hepatology, 30:156-160 (1999).
Chen, M.S., et al., “Characterization of Pyrimidine Deoxyribonucleoside Kinase (Thymidine Kinase) and Thymidylate Kinase as a Multifunctional Enzyme in Cells Transformed by Herpes Simplex Virus Type 1 and in Cells Infected with Mutant Strains of Herpes Simplex Virus,”J Virol., 30(3):942-945 (Jun. 1979).
Chen, C.-H., et al., “Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-human Immunodeficiency Virus Compound 2′,3′-Dideoxycytidine,”J. Biol. Chem., 264(20):11934-11937 (Jul. 15, 1989).
Chen, C.-H., et al., “The Role of Cytoplasmic Deoxycytidine Kinase in the Mitochondrial Effects of the Anti-human Immunodeficiency Virus Compound 2′,3′-Dideoxycytine,”J. Biol. Chem., 267(5): 2856-2859 (Feb. 15, 1992).
Cui, L., et al., “Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells,”J. of Pharmacology and Experimental Therapeutics, 280(3):1228-1234 (1997).
Davis, A.F., et al., “In Situ Localization of Mitochondrial DNA Replication in Intact Mammalian Cells,”J Cell Biol, 135(4), 883-893 (Nov. 1996).
Doong, S.-L., et al., “Inhibition of the replication of hepatitis B virusin vitroby 2′,3′-dideoxy-3′-thiacytidine and related analogues,”Proc. Natl. Acad. Sci. USA, 88:8495-8499 (Oct. 1991).
Du, J., et al, Synthesis, “Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides,”J. of Med. Chem., (40)19:2991-2993 (Sep. 12, 1997).
Dutschman, G.E., et al., “Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L-(−)-5-Fluorocytidine and Its Activity in Combination with Climically Approved Anti-Humna Immunodeficiency Virus β-D-(+) Nucleoside Analogs In Vitro,”Antimicrobial Agents and Chemotherapy, 42(7), 1799-1804 (Jul. 1998).
Furman, P.A., et al., “The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers ofcis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine”Antimicrobial Agents and Chemotherapy, 36(12):2686-2692 (Dec. 1992).
Hernandez-Santiago, B., et al., “Pharmacology of β-L-Thymidine and β-L-2′-Deoxycytidine in HepG2 Cell and Primary Human Hepatocytes: Relevance to Chemotherapeutic Efficacy against Hepatitis B Virus,”Antimicrobial Agents and Chemotherapy, 46(6), 1728-1733 (Jun. 2002).
Hoard, D.E., et al., “Conversion of Mono- and Oligodeoxyribonucleotides to 5′-Triphosphates,”J. Am. Chem. Soc., 87(8):1785-1788 (Apr. 20, 1965).
Holy, A., “Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2′-deoxy-L-Ribonucleosides of the Pyrimidine Series,”Collect. Czech. Chem. Commun., 37(12):4072-4087 (1972).
Hostetler, K.Y., et al. “Synthesis And Antiretroviral Activity Of Phospholipid Analogs Of Azidothymidine And Other Antiviral Nucleosides,”J.

Affiliated with

Also associated with

Rating

Crystalline and amorphous forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline and amorphous forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline and amorphous forms of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2767900